# FIP1L1::PDGFRA

1 EU-approved indication of 1 drug needs a FIP1L1::PDGFRA result, in 1 tumour type, most of them in myeloid/lymphoid neoplasms with eosinophilia and TK fusions.

## Approved indications by tumour

### Myeloid/lymphoid neoplasms with eosinophilia and TK fusions

| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| [Imatinib](https://oncolabels.com/drugs/imatinib) (Glivec) | FIP1L1-PDGFRalpha rearrangement | Monotherapy | Advanced | - |

## Label wording

- **Imatinib** (Glivec), Myeloid/lymphoid neoplasms with eosinophilia and TK fusions, advanced: “adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.” [SmPC](https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf)

Source: section 4.1 of each summary of product characteristics (SmPC), EMA data as of 5 Nov 2026. AI models structured these entries and no person has checked them yet. oncolabels is a non-commercial reference for education and research and gives no medical advice; the current SmPC takes precedence.

Data under CC BY 4.0: credit oncolabels and the European Medicines Agency. Page: https://oncolabels.com/biomarkers/fip1l1-pdgfra